Zobrazeno 1 - 10
of 53
pro vyhledávání: ''
Autor:
Grace Durenberger, Savannah C. Partridge, Vijayakrishna K. Gadi, Laura C Kennedy, Sasha E. Stanton, Shaveta Vinayak, Suzanne M. Dintzis
Publikováno v:
Journal of Clinical Oncology. 37:e14281-e14281
e14281 Background: Trastuzumab is an important drug in the treatment (tx) of HER2+ breast cancer, but not all tumors are responsive. Immune-enriched tumors have a better response to tx, and a biomarker to identify these tumors would be valuable. Mult
Autor:
Gabriel N. Hortobagyi, Yun Gong, Naoki Niikura, Shana L. Palla, Yutaka Tokuda, Elizabeth A. Mittendorf, Ana M. Gonzalez-Angulo, Naoki Hayashi, Naoto T. Ueno, Jun Liu
Publikováno v:
Journal of Clinical Oncology. 30:593-599
Purpose We evaluated whether patients with human epidermal growth factor receptor 2 (HER2) –positive primary breast tumors had metastatic tumors that were HER2 positive (concordant) or HER2 negative (discordant). We then evaluated whether treatment
Autor:
Ashley Cimino-Mathews, Ashley Carpenter, Antonio C. Wolff, Christos Vaklavas, Vicente Valero, Roisin M. Connolly, Melissa Camp, Anna Maria Storniolo, Vered Stearns, Chiung Yu Huang, Jennifer M. Specht, Lisa A. Carey, Jeffrey P. Leal, Minetta C. Liu, Mothaffar F. Rimawi, Vandana G. Abramson, Lilja Solnes, Robert S. Miller, Katy Gaffney, Richard L. Wahl
Publikováno v:
Journal of Clinical Oncology. 36:511-511
511Background: Predictive biomarkers to identify patients with HER2-positive breast cancer (BC) that may be treated with targeted therapy alone are of great interest. We hypothesized that early cha...
Autor:
Martine Piccart-Gebhart, Gabriel N. Hortobagyi, Richard L. Theriault, Ana M. Gonzalez-Angulo, D. Larsimont, Vicente Valero, Florentia Peintinger, Aysegul A. Sahin, Fatima Cardoso, Heidi Stranzl, Ronjay Rakkhit, Kristine Broglio, Donald A Berry, Emer O Hanrahan, Peter M. Ravdin, Merih Guray, Thomas A. Buchholz, Funda Meric-Bernstam, Jennifer K. Litton, Francesco Feoli
Publikováno v:
Journal of Clinical Oncology. 27:5700-5706
Purpose To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) –positive breast cancer. Methods We reviewed 965 T1a,bN0M0 breast cancers diagnosed at our institution be
Autor:
Kenneth Offit, Steven A. Narod
Publikováno v:
Journal of Clinical Oncology. 23:1656-1663
It has been 10 years since the BRCA1 gene was first identified. During this decade, genetic testing for breast cancer susceptibility has been incorporated into the practice of oncology. In this process, the identification of families at the highest h
Autor:
Janine LoBello, Gargi D. Basu, Joyce O'Shaughnessy, Tracey White, Matthew Halbert, Jeffrey M. Trent, Ahmet Kurdoglu, Thomas Royce
Publikováno v:
Journal of Clinical Oncology. 35:1040-1040
1040 Background: Mutations (mut) in ESR1 have been reported in ER+ breast cancers (BC) as an acquired resistance mut to aromatase inhibitor (AI) therapy. Acquired ERBB2 mut have also been reported in MBC patients (pts) that cause activated ERBB2 sign
Autor:
Kazuya Suzuki, Hiroyuki Kaneto, Yoshiaki Arimura, Mitsuru Yoshimoto, Yasuo Hamamoto, Mayuko Saito, Kentaro Yamashita, Tokuma Tanuma, Atsushi Yawata, Hiroshi Nakase, Hiroyuki Okuda, Takeya Adachi, Kohei Nakachi
Publikováno v:
Journal of Clinical Oncology. 35:29-29
29 Background: Recent studies showed that serum HER2 levels correlated with tissue HER2 status in gastric cancer. The aim of this prospective study (UMIN000006442, 000006445) was to investigate changes in serum HER2 levels and tissue HER2 status duri
Autor:
Josef Thaler, Bjoern Jagdt, Richard Greil, Wolfgang Eisterer, Ewald Woell, Johannes Andel, Michael A. Fridrik, Bernd L. Hartmann, Horst Oexle, Christoph Tinchon, Peter Regitnig, Alois Wuestner
Publikováno v:
Journal of Clinical Oncology. 34:e15501-e15501
e15037 Background: Trastuzumab plus chemotherapy is the treatment of choice for locally advanced or metastatic gastric cancer patients. Pathological assessment of gastric cancer specimens, especially biopsy samples, however still remains difficult al
Autor:
Tadeusz Pienkowski, Dennis J. Slamon, Ivonne Villalobos, Yanling Ma, John R. Mackey, Marc Buyse, Nicholas J. Robert, Vicente Valero, E. Quinaux, Wolfgang Eiermann, Denice D. Tsao-Wei, John Crown, Michael F. Press, Mary-Ann Lindsay, Guido Sauter, Martina Mirlacher, Miguel Martín, Hélène Fourmanoir, V. Bee-Munteanu, Anaamika Campeau
Publikováno v:
Journal of Clinical Oncology. 34:515-515
515Background: ASCO-CAP recently recommended further changes to evaluation of HER2 gene amplification by FISH. We retrospectively assessed the impact of the guidelines using annotated BCIRG-005, BCIRG-006, and BCIRG-007 clinical trial data for which
Autor:
Mohammed Salama, Alex Farr, Georg Pfeiler, Elisabeth Oppolzer, Zsuzsanna Bago-Horvath, Christian F. Singer, Michael Seifert, Myriam Weber
Publikováno v:
Journal of Clinical Oncology. 34:e12500-e12500
e12500Background: The proliferation marker Ki67 is an established prognostic and predictive marker in breast cancer. The association between Ki67 and treatment response in the neoadjuvant setting, however, is still unclear. We have therefore evaluate